EDAP Continues Its Growth Strategy; Enters New Major Market for Lithotripsy
21 January 2011 - 1:15AM
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic
ultrasound, reported today placement of the first Sonolith i-sys
electroconductive lithotripter in South Africa.
Pretoria Urology Hospital (PUH) is the largest private urology
hospital in South Africa, entirely dedicated to treating urology
disorders ranging from urinary stones to prostate cancer. A medical
team of fourteen urologists at PUH is actively focusing on offering
best-in-class treatment options to patients and has been using
EDAP's Ablatherm-HIFU technology to successfully treat prostate
cancer for over a year. More than 600 lithotripsy treatments are
performed every year at PUH, together with associated endourology
procedures. Sonolith i-sys fully integrated system is the ideal
treatment to meet PUH's lithotripsy needs.
Mr. Gary Wachsberger, Director of Intamed, EDAP's distribution
partner in South Africa, commented, "We have enjoyed a long term
relationship with EDAP to distribute their best-in-class urology
devices in South Africa and have successfully introduced the
Company's Ablatherm-HIFU device. We are excited to now place the
first electroconductive Sonolith i-sys in South Africa. Its
compelling efficacy and superiority will allow patients to benefit
from the industry leading technology to treat their urinary stones.
We are very optimistic about additional placement opportunities for
EDAP's range of Sonolith devices."
Marc Oczachowski, Chief Executive Officer of EDAP, added, "We
are actively pursuing our global expansion strategy of entering new
and growing markets. We are very excited to move forward the entry
of EDAP in the major African markets, with the first installation
of our innovative and leading integrated lithotripsy system, the
Sonolith i-sys. This is another successful milestone in our
aggressive strategy to penetrate new markets and take more market
share thanks to our unique and fully renewed range of
lithotripters."
Marc Oczachowski concluded, "We continue to work actively on
pushing forward our regulatory programs in major markets and are on
track for Sonolith i-move approvals in the U.S. and major
international markets."
Intamed is part of Intamarket Group that has specialized in the
distribution of high technology products for more than 35 years.
Intamed distributes medical devices and consumables capital medical
equipment on behalf of significant international brands to the
healthcare industry in South Africa and neighboring countries.
About EDAP TMS SA
EDAP TMS SA develops and markets Ablatherm, the most advanced
and clinically proven choice for high-intensity focused ultrasound
(HIFU) treatment of localized prostate cancer. HIFU treatment is
shown to be a minimally invasive and effective treatment option
with a low occurrence of side effects. Ablatherm-HIFU is generally
recommended for patients with localized prostate cancer (stages
T1-T2) who are not candidates for surgery or who prefer an
alternative option, or for patients who failed radiotherapy
treatment. Approved in Europe as a treatment for prostate cancer,
Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently
undergoing evaluation in a multicenter U.S. Phase II/III clinical
trial under an Investigational Device Exemption granted by the FDA,
the ENLIGHT U.S. clinical study. The Company also is developing
this technology for the potential treatment of certain other types
of tumors. EDAP TMS SA also produces and commercializes medical
equipment for treatment of urinary tract stones using
extra-corporeal shockwave lithotripsy (ESWL). For more information
on the Company, please visit http://www.edap-tms.com,
http://www.hifu-planet.com.
CONTACT: Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 72
bconfort@edap-tms.com
Investors:
Stephanie Carrington
The Ruth Group
646-536-7017
scarrington@theruthgroup.com
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jun 2024 to Jul 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jul 2023 to Jul 2024